Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies
- 4 November 2020
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 34 (11) , 1149-1163
Abstract
Levodopa is the most effective drug for the treatment of Parkinson’s disease, but its use as an oral medication is complicated by its erratic absorption, extensive metabolism and short plasma half-life. On long-term use and with disease progression, there is a high incidence of motor and non-motor complications, which remain a major clinical and research challenge. It is widely accepted that levodopa needs to be administered using formulations that result in good and consistent bioavailability and the physiologically relevant and continuous formation of dopamine in the brain to maximise its efficacy while avoiding and reversing ‘wearing off’ and dyskinesia. However, the physicochemical properties of levodopa along with its pharmacokinetic and pharmacodynamic profile make it difficult to deliver the drug in a manner that fulfils these criteria. In this review, we examine the problems associated with the administration of levodopa in Parkinson’s disease and how the use of novel technologies and delivery devices is leading to a more consistent and sustained levodopa delivery with the aim of controlling motor function as well as non-motor symptoms.Keywords
This publication has 92 references indexed in Scilit:
- Wearing Off, Dyskinesia, and the Use of Continuous Drug Delivery in Parkinson's DiseaseNeurologic Clinics, 2013
- Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteersActa Neurologica Scandinavica, 2012
- Pharmacokinetics and Pharmacodynamics of Gastroretentive Delivery of Levodopa/Carbidopa in Patients With Parkinson DiseaseClinical Neuropharmacology, 2012
- Parkinson’s disease: The non-motor issuesParkinsonism & Related Disorders, 2011
- Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's diseaseMovement Disorders, 2011
- Levodopa in the treatment of Parkinson’s disease: an old drug still going strongClinical Interventions in Aging, 2010
- Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of lifeMovement Disorders, 2009
- Levodopa: Past, Present, and FutureEuropean Neurology, 2008
- Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate MuscleJournal of Virology, 2008
- Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primatesExperimental Neurology, 2005